BridgeBio Pharma, Inc.
BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 cliniā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$72.50
Price-4.71%
-$3.58
1Y
Price
Market Cap
$14.200b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-61.4%
EBITDA Margin-68.4%
Net Profit Margin-100.6%
Free Cash Flow Margin-61.4%
EBITDA Margin-68.4%
Net Profit Margin-100.6%
Free Cash Flow MarginRevenue
$691.835m
+37.8%
1y CAGR+816.4%
3y CAGR+590.3%
5y CAGREarnings
-$696.240m
+4.5%
1y CAGR-5.0%
3y CAGR-12.1%
5y CAGREPS
-$3.58
+5.5%
1y CAGR+0.3%
3y CAGR-4.2%
5y CAGRBook Value
-$2.506b
$1.217b
Assets$3.723b
Liabilities$2.494b
DebtDebt to Assets
204.9%
-4.1x
Debt to EBITDAFree Cash Flow
-$592.121m
-32.5%
1y CAGR-5.6%
3y CAGR-10.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company